• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

50.39 -0.87 (-1.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 922,202
Open 51.02
Bid (Size) 50.66 (900)
Ask (Size) 55.00 (500)
Prev. Close 51.26
Today's Range 49.98 - 53.00
52wk Range 6.710 - 53.65
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗
February 18, 2026
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise... 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance

Performance

YTD
+26.7%
+26.7%
1 Month
+7.3%
+7.3%
3 Month
+26.9%
+26.9%
6 Month
+116.7%
+116.7%
1 Year
+338.6%
+338.6%

More News

Read More
News headline image
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗
February 16, 2026
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗
February 01, 2026
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
January 07, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
December 08, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
November 04, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 06, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
September 17, 2025
Via MarketBeat
News headline image
What's going on in today's session ↗
September 11, 2025
Via Chartmill
News headline image
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential ↗
September 11, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
September 11, 2025
Via Benzinga
News headline image
Which stocks are moving on Thursday? ↗
September 11, 2025
Via Chartmill
News headline image
Maze Therapeutics, Opendoor Technologies, Oxford Industries, VNET Group And Other Big Stocks Moving Higher On Thursday ↗
September 11, 2025
Via Benzinga
News headline image
Thursday's session: gap up and gap down stocks ↗
September 11, 2025
Via Chartmill
News headline image
Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results ↗
September 11, 2025
Via Investor's Business Daily
News headline image
Discover the top movers in Thursday's pre-market session. ↗
September 11, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
September 11, 2025
Via Benzinga
News headline image
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
September 11, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
September 02, 2025
From Maze Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Maze Therapeutics, Inc. - Common Stock publicly traded?
Yes, Maze Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Maze Therapeutics, Inc. - Common Stock trade on?
Maze Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maze Therapeutics, Inc. - Common Stock?
The ticker symbol for Maze Therapeutics, Inc. - Common Stock is MAZE on the Nasdaq Stock Market
What is the current price of Maze Therapeutics, Inc. - Common Stock?
The current price of Maze Therapeutics, Inc. - Common Stock is 50.39
When was Maze Therapeutics, Inc. - Common Stock last traded?
The last trade of Maze Therapeutics, Inc. - Common Stock was at 03/17/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap